Tag Archives: siRNA

Inhibitory RNA miR-182 Can Turn-Off Glioblastoma

Researchers examined large-scale genomic datasets and found that patients with higher levels of miR-182 had a better chance of surviving glioblastoma (GBM) longer. This prompted them to perform pre-clinical studies to elucidate the mechanism by which miR-182 acts. Continue reading

IND for Clinical Studies of dCellVax Breast Cancer Immune Therapy Filed – Intelligent and Rational Gene Silencing Approach for Cancer

Regen Biopharma recently filed an IND (Investigational New Drug Application) with the FDA to permit the initiation of Phase 1 clinical trials of its dCellVax treatment for advanced breast cancer. Continue reading

IDO inhibition in cancer immunology

IDO ( indoleamine 2,3-dioxygenase) is a molecule that oxidizes tryptophan, which is needed by cytotoxic T-cells. When cancer cells and T-reg cells secrete IDO in the vicinity of cytotoxic T cells, antitumor activity is abrogated.   Continue reading